Form 4: BioLife Solutions Chief Marketing Officer Sells Shares Under 10b5-1 Plan

Todd Berard, Chief Marketing Officer of BioLife Solutions, sold 343 shares of common stock at $27.02 per share on January 6, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Todd Berard, the Chief Marketing Officer of BioLife Solutions, executed a sale of 343 shares of the company's common stock.
• The transaction occurred on January 6, 2025, at a price of $27.02 per share.
• This sale was conducted under a pre-existing Rule 10b5-1 trading plan, which was adopted on January 3, 2023.
• The purpose of the sale was to cover tax withholding obligations related to the vesting of restricted stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing for an insider stock sale under a pre-arranged plan, which is neutral in sentiment.

Industry Context

This is a routine filing related to insider trading activity and is common for executives who have stock-based compensation. It does not indicate any specific trend in the industry.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a common practice among publicly traded companies to allow insiders to sell shares while avoiding accusations of trading on non-public information.
• Many executives at comparable companies such as Thermo Fisher Scientific (TMO) and Danaher Corporation (DHR) also utilize 10b5-1 plans for stock transactions.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on shareholder sentiment, but it is unlikely to be significant given the pre-planned nature of the transaction.

Key Dates

Keywords

BioLife Solutions, BLFS, insider trading, Form 4, Todd Berard, Rule 10b5-1, stock sale, executive, Chief Marketing Officer